RÉSUMÉ
RESUMEN La Organización Mundial de la Salud (OMS) ubica a la tuberculosis (TB) como uno de los problemas de salud más preocupantes en la actualidad, y señala que se requieren de acciones novedosas para controlar su expansión y, de esta manera, alcanzar una de las metas establecidas en los Objetivos de Desarrollo Sostenible: reducir para 2030 la morbilidad e incidencia de TB. Para lograr este objetivo, está claro que las herramientas empleadas actualmente para su diagnóstico y tratamiento ya no son las adecuadas. En este sentido, es necesario desarrollar nuevos medicamentos y vacunas, así como novedosos procedimientos de administración de fármacos que generen una mejor respuesta, disminuyan el tiempo y optimicen los tratamientos. La nanotecnología ha incorporado en los últimos años un gran número de nuevas herramientas que incrementan considerablemente, la diversidad de mecanismos para la administración de tratamientos antituberculosos. Dicho esto, la presente revisión describe brevemente el estado actual de la farmacorresistencia en TB, así como las características generales de las nanopartículas que están evaluándose como herramientas para transportar antibióticos antituberculosos.
ABSTRACT The World Health Organization (WHO) places Tuberculosis (TB) as one of the most important health problems today. According to the WHO, this disease requires novel actions to control its expansion and, in this way, achieve one of the goals established in the sustainable development goals: to reduce TB morbidity and incidence by 2030 and regain control. To achieve this goal, the tools currently used for diagnosis and treatment are no longer adequate. In this sense, it is necessary to develop new drugs and vaccines, as well as novel drug administration procedures that generate a better response, reduce times, and optimize treatments. Nanotechnology has incorporated in recent years a considerable number of new tools that significantly increase the diversity of mechanisms for the administration of anti-tuberculosis drugs. Therefore, the present review briefly describes the current state of drug resistance in tuberculosis, as well as the general characteristics of nanoparticles being evaluated as tools to transport new antibiotics against tuberculosis.
Sujet(s)
Tuberculose , Nanoparticules , Antibiotiques antituberculeux , Transport biologique , Résistance microbienne aux médicaments , Vecteurs de médicaments , Morbidité , Anti-infectieuxRÉSUMÉ
RESUMEN La Organización Mundial de la Salud (OMS) ubica a la tuberculosis (TB) como uno de los problemas de salud más preocupantes en la actualidad, y señala que se requieren de acciones novedosas para controlar su expansión y, de esta manera, alcanzar una de las metas establecidas en los Objetivos de Desarrollo Sostenible: reducir para 2030 la morbilidad e incidencia de TB. Para lograr este objetivo, está claro que las herramientas empleadas actualmente para su diagnóstico y tratamiento ya no son las adecuadas. En este sentido, es necesario desarrollar nuevos medicamentos y vacunas, así como novedosos procedimientos de administración de fármacos que generen una mejor respuesta, disminuyan el tiempo y optimicen los tratamientos. La nanotecnología ha incorporado en los últimos años un gran número de nuevas herramientas que incrementan considerablemente, la diversidad de mecanismos para la administración de tratamientos antituberculosos. Dicho esto, la presente revisión describe brevemente el estado actual de la farmacorresistencia en TB, así como las características generales de las nanopartículas que están evaluándose como herramientas para transportar antibióticos antituberculosos.
ABSTRACT The World Health Organization (WHO) places Tuberculosis (TB) as one of the most important health problems today. According to the WHO, this disease requires novel actions to control its expansion and, in this way, achieve one of the goals established in the sustainable development goals: to reduce TB morbidity and incidence by 2030 and regain control. To achieve this goal, the tools currently used for diagnosis and treatment are no longer adequate. In this sense, it is necessary to develop new drugs and vaccines, as well as novel drug administration procedures that generate a better response, reduce times, and optimize treatments. Nanotechnology has incorporated in recent years a considerable number of new tools that significantly increase the diversity of mechanisms for the administration of anti-tuberculosis drugs. Therefore, the present review briefly describes the current state of drug resistance in tuberculosis, as well as the general characteristics of nanoparticles being evaluated as tools to transport new antibiotics against tuberculosis.
Sujet(s)
Tuberculose , Résistance microbienne aux médicaments , Nanoparticules , Transport biologique , Préparations pharmaceutiques , Morbidité , Anti-infectieux , Antibiotiques antituberculeuxRÉSUMÉ
High density lipoprotein ( HDL ) has been considered as an important mediator in favoring cardioprotective effects .However , recent studies revealed that HDL-C-raising therapeutics alone failed to reduce the risk of cardiovascular diseases , suggesting that the HDLfunctionalitymay be more critical for its cardioprotective properties than the simple HDL-C levels.microRNAs ( miRNAs) have been identified as the novel regulators of lipid metabolism and played essential roles in the key steps of reverse cholesterol transport, involving in HDL biogenesis , cellular cholesterol mobilization , hepatic HDL uptake and excretion.The intensive research on lipid metabolism-related miRNAs may provide further clarification on the molecular regulatory mechanisms for HDL-mediated reverse cholesterol transport and plasma HDL-C levels, advancing our knowledge on the effects of HDL in pathogenesis and progression of cardiovascular diseases.
RÉSUMÉ
As a novel fluorescent nanomaterial,quantum dots (QDs) have a prospect for wide application. However , the adverse effects of QDs have become a concern among and more researchers. The toxic actions of QDs in vivo are closely associated with the biotransport and bio?transformation of QDs,which can be affected by the exposure pathways,exposure dose,surface modification and the particle size. Among them,the exposure pathways can affect the absorption and distribution of QDs in vivo,the exposure dose can affect the metabolism and excretion,thus influencing the distribution of QDs in vivo ,the surface modification can affect the distribution ,metabolism and excretion of QDs in vivo,the particle size can affect the absorption,distribution and excretion of QDs in vivo,and larger QDs are more likely to remain in the body and difficult to remove. QDs can enter the body through the circulatory system,get accumulated and degraded in the liver,kidney and other organs. The degraded products can be excerted through excrement and urine under the metabolism in the liver,spleen and kidneys. In addition,QDs can interact with biological macromolecules in the body,causing DNA damage,affecting the function and gene expression level of the liver,kidney,nervous system and other organs,and resulting in pathological and functional damage to tissues and organs.
RÉSUMÉ
Endolaryngeal injection of botulinum toxin into the thyroarytenoid (TA) muscle is one of the methods for treatment of focal laryngeal dystonia. However, after treatment, there is variation in laryngeal configuration as well as the side effects reported by patients. As a consequence of the functional variability of results, it was hypothesized that botulinum toxin diffuses beyond the limits of the muscle into which it is injected. OBJECTIVES: After injection of botulinum toxin into the TA muscle for the treatment of focal laryngeal dystonia, patients differ in terms of laryngeal configuration and side effects. We hypothesized that this toxin diffuses from the target muscle to adjacent muscles. METHOD: The TA muscles of 18 cadaver larynges were injected with aniline blue (0.2 mL). After fixation in formaldehyde and nitric acid decalcification, the larynges were sectioned in the coronal plane and the intrinsic muscles were analyzed. RESULTS: We found diffusion of aniline blue to the lateral cricoarytenoid muscle, cricothyroid muscle, and posterior cricoarytenoid muscle in 94.3%, 42.9%, and 8.6% of the cases, respectively. In terms of the degree of diffusion to adjacent muscles, we found no differences related to the size (height and width) of the TA muscle or to gender. CONCLUSIONS: Our findings suggest that diffusion of botulinum toxin from its injection site in the TA muscle to the lateral cricoarytenoid muscle is likely in most cases. On the other hand, diffusion to the cricothyroid muscle occurs in approximately half of cases and diffusion to the posterior cricoarytenoid muscle occurs in very few cases...
Sujet(s)
Humains , Toxines botuliniques , Dysphonie , Muscles du larynx/anatomopathologie , Transport biologique , Cadavre , LarynxRÉSUMÉ
Com o avanço da tecnologia na área de diagnóstico clínico, tanto a descoberta quanto o acompanhamento de diversas patologias tem se tornado mais rápidos, práticos e confiáveis. Estes diagnósticos, cada vez mais específicos, se tornam inviáveis para laboratórios de pequeno e médio porte, devido ao alto custo de suas metodologias. A terceirização é uma alternativa para estes laboratórios, quando necessitam de análises de alta complexidade. Porém, muitas vezes, o baixo custo gerado pela terceirização pode comprometer a qualidade do exame realizado, devido à logística envolvida desde a coleta até a realização dos exames nos laboratórios de apoio. Neste sentido, foi avaliada, de forma preliminar, a qualidade das dosagens bioquímicas enviadas e realizadas em um laboratório de apoio (terceirizado), a fim de refletir sobre o impacto da terceirização na qualidade dos serviços executados em um laboratório clínico.
Technological advancements for clinical diagnostics allow for assessing more rapid, convenient and reliable results. However, these diagnoses, increasingly specific, become unviable for small and medium labs due to their costly methodologies. Thus, Outsourcing of tasks is an alternative to highly complex analyzes, though the cost generated of outsourcing can compromise the quality of the examination, due to the logistics involved from collection to the examinations in laboratories support. In this sense, the quality of biochemical markers performed in an outsourced laboratory was evaluated to reflect the impact of outsourcing on the quality of services.
RÉSUMÉ
Objective To explore the optimum flow shear stress and mass transport for the construction of tissue-engineered bone.Methods The β-tricalcium phosphate (β-TCP) scaffolds seeded with human bone marrow-derived mesenchymal stem cells (HBMMSCs) were cultured in perfusion bioreactor.When the same flow rate was applied,the flow shear stress was separately 1×,2× and 3×.When the same flow shear stress was applied,the flow rates were separately 3 ml/min,6 ml/min and 9 ml/min.Cell proliferation was measured by MTT method.The construction of tissue-engineered bone was evaluated by measuring alkaline phosphatase (AKP) activity,secretion of osteopontin (OP) and osteocalcin (OC),and the mineralization of extracellular matrix (ECM).The flow shear stress and the mass transport were obtained using computational fluid dynamics.Results When the flow rate was same,the most cell proliferation was found in 2× group.The AKP activity and secretion of OC was higher in 2× and 3× groups than in those in 1× group.After 28days,the highest amount of mineralization of ECM was found in 3× group.When the flow shear stress was same,the AKP activity was highest in 6 ml/min group.After 28 days,secretion of OC and formation of mineralized ECM was highest in 3 ml/min group.When the flow rate was same,the flow shear stress was separately 0.004-0.007 Pa,0.009-0.013 Pa and 0.013-0.018 Pa.When the flow shear stress was same,the flow rate was separately 0.267-0.384 mm/s,0.521-0.765 mm/s and 0.765-1.177 mm/s.Conclusion When the tissue-engineered bone was constructed,0.013-0.018 Pa flow shear stress and 0.267-0.384 mm/s mass transport velocity could improve the construction of the tissue-engineered bone in vitro.